SCHEMBL8290769

SCHEMBL8290769

CCOC(=O)c1c(NC(=O)c2ccccc2F)sc2c1CCC2

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.79
TP53 P04637 1/20 0.79
CNR2 P34972 2/20 0.72
CNR1 P21554 1/20 0.72
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
HPGD P15428 5/20 0.68
ALDH1A1 P00352 5/20 0.68
HSD17B10 Q99714 4/20 0.68
KDM4E B2RXH2 4/20 0.68
TSHR P16473 2/20 0.68
USP2 O75604 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.67
NPC1 O15118 2/20 0.67
RAB9A P51151 2/20 0.67
LMNA P02545 2/20 0.67
NPSR1 Q6W5P4 2/20 0.67
CASP1 P29466 1/20 0.67
CASP7 P55210 1/20 0.67
TLR2 O60603 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13561104 0.88 MAPT (1.00) MAPTTP53CNR2CNR1MEN1
SCHEMBL8290510 0.85 MAPT (0.77) MAPTTP53CNR2CNR1MEN1
SCHEMBL3916162 0.83 MAPT (0.80) MAPTTP53CNR2CNR1HPGD
SCHEMBL16562058 0.81 MAPT (0.80) MAPTTP53CNR2MEN1KMT2A
SCHEMBL14328953 0.81 MAPT (0.74) MAPTTP53CNR2CNR1MEN1
SCHEMBL18104300 0.81 MEN1 (0.77) MAPTTP53CNR2CNR1MEN1
SCHEMBL34468494 0.80 MAPT (0.70) MAPTTP53CNR2HPGDALDH1A1
SCHEMBL19475085 0.80 MAPT (0.68) MAPTTP53CNR2HPGDALDH1A1
SCHEMBL34468525 0.80 MAPT (0.76) MAPTTP53CNR2HPGDALDH1A1
SCHEMBL13235100 0.80 TLR2 (1.00) MAPTTP53CNR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051220-A1 COMPOUNDS FOR USE IN THERAPY GLUCOX BIOTECH AB (SE) 2015-02-19 US disclosed
EP-2825165-A1 THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY Glucox Biotech AB (SE) 2015-01-21 EP disclosed
WO-2013135803-A1 THIOPHENE-BASED COMPOUNDS EXHIBITING NOX4 INHIBITORY ACTIVITY AND USE THEREOF IN THERAPY GLUCOX BIOTECH AB (SE) 2013-09-19 WO disclosed
WO-2005033102-A2 THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMPHORA DISCOVERY CORPORATION (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051220-A1 COMPOUNDS FOR USE IN THERAPY XDH, PNPO, OAT MAPT 1102/4885TP53 4080/4885CNR2 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.